A Phase 1 Study of ICP-248 in Combination with Azacitidine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are Not Eligible for Standard Anthracycline-Based Induction or Previously Treated Relapsed/Refractory Subjects with Acute Myelogenous Leukemia
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Mesutoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors InnoCare Pharma
Most Recent Events
- 27 Dec 2024 Planned number of patients changed from 90 to 102.
- 27 Dec 2024 Status changed from not yet recruiting to recruiting.
- 24 Oct 2024 Status changed to not yet recruiting.